TABLE 1.
Baseline characteristics of hepatitis C virus (HCV) treatment recipients, stratified by oral cannabinoid-containing medication (OC) use
| OC use
|
||
|---|---|---|
| Yes (n=25) | No (n=166) | |
| Age, years, mean ± SD | 44±7 | 43±10 |
| Weight, kg, mean ± SD | 78±19 | 79±17 |
| HCV RNA, copies/mL, mean ± SD | 1.1×106±1.7×106 | 1.2×106±1.9×106 |
| ALT level, U/L, mean ± SD | 73±52 | 101±78 |
| Sex, n (%) | ||
| Male | 18 (72) | 125 (75) |
| Female | 7 (28) | 41 (25) |
| HCV genotype, n (%) | ||
| 1 | 18 (73) | 102 (61) |
| 2 | 2 (8) | 20 (12) |
| 3 | 5 (20) | 39 (23) |
| 4 | 0 (0) | 5 (3) |
| Ethnic background, n (%) | ||
| White | 24 (96) | 148 (89) |
| Other | 1 (4) | 18 (11) |
| Country of birth, n (%) | ||
| Canadian-born | 22 (88) | 138 (83) |
| Immigrant | 3 (12) | 28 (17) |
| Liver biopsy stage (METAVIR), n (%)* | ||
| 0–2 | 10 (53) | 67 (68) |
| 3–4 | 9 (47) | 32 (32) |
| HIV coinfection, n (%) | 5 (20) | 14 (9) |
| Psychiatric illness history | 13 (52) | 86 (52) |
| Injection drug use history | 18 (72) | 98 (59) |
| Excess alcohol use history | 18 (72) | 100 (60) |
| Alcohol or drug abuse history | 22 (88) | 130 (78) |
| Marijuana smoking history | 6 (24) | 16 (10) |
*
Nineteen of 25 patients and 99 of 166 patients underwent pretreatment liver biopsy. ALT Alanine aminotransferase